Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Teva
Chubb
Moodys
Baxter
QuintilesIMS
Colorcon
Julphar
Farmers Insurance

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,611,724

« Back to Dashboard

Which drugs does patent 7,611,724 protect, and when does it expire?

Patent 7,611,724 protects ISTODAX and is included in one NDA.

This patent has five patent family members in five countries.
Summary for Patent: 7,611,724
Title:Method of producing FR901228
Abstract:Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. Also provided are crystalline forms of FR901228, e.g., type A and type B crystalline forms of FR901228.
Inventor(s): Ueda; Satoshi (Chuo-ku, JP), Watamoto; Yoko (Chuo-ku, JP), Tsuboi; Masaru (Chuo-ku, JP), Kanda; Munekazu (Chuo-ku, JP), Higaki; Tomoji (Chuo-ku, JP), Matsuda; Mitsunori (Chuo-ku, JP)
Assignee: Astellas Pharma Inc. (Tokyo, JP)
Application Number:12/396,773
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,611,724
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,611,724

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Celgene ISTODAX romidepsin POWDER;IV (INFUSION) 022393-001 Nov 5, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,611,724

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-265414Sep 01, 2000

Non-Orange Book US Patents Family Members for Patent 7,611,724

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,445,634 Method of producing FR901228 ➤ Try a Free Trial
7,396,665 Method of producing FR901228 ➤ Try a Free Trial
9,371,361 Method of producing FR901228 ➤ Try a Free Trial
8,426,556 Method of producing FR901228 ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,611,724

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 030714 ➤ Try a Free Trial
Australia 8010901 ➤ Try a Free Trial
European Patent Office 1313872 ➤ Try a Free Trial
Japan 2004508049 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Teva
US Army
McKesson
Covington
Cerilliant
McKinsey
Boehringer Ingelheim
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.